Search

Your search keyword '"Funel, Niccola"' showing total 555 results

Search Constraints

Start Over You searched for: Author "Funel, Niccola" Remove constraint Author: "Funel, Niccola"
555 results on '"Funel, Niccola"'

Search Results

1. A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease

5. Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds

6. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer

11. Supplementary Figure 2 from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells

12. Supplementary Figure 1 from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells

13. Supplementary Figure Legend from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells

15. Supplementary Figures 1-3, Tables 1-6 from Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer

16. Supplementary Figure 1 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma

17. Data from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma

18. Supplementary Methods from MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity

19. Supplementary Figure 3 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma

20. Supplementary Figure 8 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma

21. Supplementary Figure 6 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma

22. Supplementary Figure 4 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma

23. Supplementary Figure 7 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma

24. Supplementary Figures 1-5 from MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity

25. Supplementary Methods from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma

26. Data from MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity

27. Supplementary Video from MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity

28. Supplementary Figure Legend from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma

29. Supplementary Figure 5 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma

30. Supplementary Video 1 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma

31. Supplementary Figure 2 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma

33. Robotic-assisted versus open left pancreatectomy for cystic tumours: A single-centre experience

34. Dysregulated insulin secretion is associated with pancreatic β‐cell hyperplasia and direct acinar‐β‐cell trans‐differentiation in partially eNOS ‐deficient mice

35. Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms

36. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms

38. Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium

41. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk

42. Detailing the ultrastructure’s increase of prion protein in pancreatic adenocarcinoma

43. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility

46. Silver Nanoparticle-Coated Polyhydroxyalkanoate Based Electrospun Fibers for Wound Dressing Applications

47. Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients

48. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk

Catalog

Books, media, physical & digital resources